These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 25801557)
21. Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. Gastine S; Lehrnbecher T; Müller C; Farowski F; Bader P; Ullmann-Moskovits J; Cornely OA; Groll AH; Hempel G Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038273 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217 [TBL] [Abstract][Full Text] [Related]
23. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563 [TBL] [Abstract][Full Text] [Related]
24. Voriconazole: A Review of Population Pharmacokinetic Analyses. Shi C; Xiao Y; Mao Y; Wu J; Lin N Clin Pharmacokinet; 2019 Jun; 58(6):687-703. PubMed ID: 30687893 [TBL] [Abstract][Full Text] [Related]
25. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children. Espinoza N; Galdames J; Navea D; Farfán MJ; Salas C Sci Rep; 2019 Jun; 9(1):8863. PubMed ID: 31222084 [TBL] [Abstract][Full Text] [Related]
26. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision? Zhong X; Tong X; Ju Y; Du X; Li Y Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899 [TBL] [Abstract][Full Text] [Related]
27. Predictive Value of C-Reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation. Takahashi T; Jaber MM; Smith AR; Jacobson PA; Fisher J; Kirstein MN J Clin Pharmacol; 2022 Jul; 62(7):855-862. PubMed ID: 34970774 [TBL] [Abstract][Full Text] [Related]
28. Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. McDougall DA; Martin J; Playford EG; Green B J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):165-77. PubMed ID: 26676909 [TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Karlsson MO; Lutsar I; Milligan PA Antimicrob Agents Chemother; 2009 Mar; 53(3):935-44. PubMed ID: 19075073 [TBL] [Abstract][Full Text] [Related]
30. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636 [TBL] [Abstract][Full Text] [Related]
31. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses. Yamada T; Mino Y; Yagi T; Naito T; Kawakami J Biol Pharm Bull; 2015; 38(10):1496-503. PubMed ID: 26424015 [TBL] [Abstract][Full Text] [Related]
33. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach. Tang D; Song BL; Yan M; Zou JJ; Zhang M; Zhou HY; Wang F; Xiao YW; Xu P; Zhang BK; Chen XJ; Xiang DX; Linh Banh H Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):34-43. PubMed ID: 30715804 [TBL] [Abstract][Full Text] [Related]
34. Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization. Li S; Wu S; Gong W; Cao P; Chen X; Liu W; Xiang L; Wang Y; Huang J Front Pharmacol; 2021; 12():730826. PubMed ID: 35046798 [No Abstract] [Full Text] [Related]
35. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. Bennis Y; Bodeau S; Bouquié R; Deslandes G; Verstuyft C; Gruson B; Andréjak M; Lemaire-Hurtel AS; Chouaki T Br J Clin Pharmacol; 2015 Oct; 80(4):782-4. PubMed ID: 26138512 [No Abstract] [Full Text] [Related]
36. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450 [TBL] [Abstract][Full Text] [Related]
37. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes. Wang P; Liu S; Yang J Clin Pharmacol Ther; 2024 Aug; 116(2):363-371. PubMed ID: 38429919 [TBL] [Abstract][Full Text] [Related]